Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 331.00
Bid: 328.00
Ask: 333.00
Change: 10.50 (3.28%)
Spread: 5.00 (1.524%)
Open: 316.50
High: 333.00
Low: 315.00
Prev. Close: 320.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica bullish; Petrofac slumps

Mon, 29th Apr 2024 10:42

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

----------

SMALL-CAP - WINNERS

----------

Oxford BioMedica PLC, up 6.9% at 244.25 pence, 12-month range 164.29p-474.50p. The gene and cell-therapy company says it is seeing decent demand for its contract development and manufacturing organisation offering, as it moves away from the Covid-19 vaccine era. Oxford BioMedica's revenue in 2023 falls 36% to GBP89.5 million from GBP140.0 million and its pretax loss stretches to GBP188.5 million from GBP46.0 million. Hurting its bottom line is a GBP99.3 million impairment of assets booked in the US business, "driven by the cessation of revenues from Homology". Homology Medicines Inc is a genetic medicines company and client of Oxford Biomedica US. More promisingly, Oxford BioMedica reports a "small increase in core business" revenue. Chief Executive Officer Frank Mathias comments: "2023 was a year of transformation for Oxford Biomedica. We are building our position as a global pure-play cell and gene therapy CDMO and through our 'One OXB' strategy are unifying our operations in the UK, US and the EU, including our newly-acquired sites in France...Despite challenging market conditions, we continue to see strong demand for our CDMO services, further solidifying our position as a world-leading global CDMO in the rapidly expanding cell and gene therapy market."

----------

Digital 9 Infrastructure PLC, up 3.9% at 22.03 pence, 12-month range 14.50p-72.00p. The investor in internet infrastructure, such as data centres and subsea fibre receives a USD25 million deferred consideration payment in connection with its sale of Verne Global. Digital 9 plans an additional GBP47 million repayment and partial cancellation of its revolving credit facility.

----------

SMALL-CAP - LOSERS

----------

Petrofac Ltd, down 31% at 15.46p, 12-month range 13.91p-87.50p. It warns a financial restructuring could see a chunk of its debt converted to equity, resulting in dilution of existing shareholders. The energy infrastructure company also flags an extra USD130 million charge in its engineering and construction division and said the release of full-year results would be delayed.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Aug 2022 14:30

EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

Read more
26 Jul 2022 11:12

SMALL-CAP WINNERS & LOSERS: Reach and Wickes sink on dark outlook

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Read more
26 Jul 2022 11:09

Oxford BioMedica begins new project and signs license agreement

(Alliance News) - Oxford BioMedica PLC on Tuesday said it started a new project and signed a license and supply agreement.

Read more
26 Jul 2022 08:44

Oxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics

(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with Orchard Therapeutics.

Read more
22 Jul 2022 10:36

SMALL-CAP WINNERS & LOSERS: Made.com and Hochschild slide again

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
21 Jul 2022 11:13

IN BRIEF: Oxford BioMedica shares up on deal expansion in CAR-T

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Expands its license and clinical supply agreement with Juno Therapeutics Inc, subsidiary of New-York based pharmaceutical industry company Bristol Myers Squibb. It says the expansion relates to the start of two new viral vector programmes for CAR-T therapies. "Oxford Biomedica will receive an undisclosed target nomination fee and potential payments upon the achievement of certain milestones," it notes.

Read more
21 Jul 2022 10:28

SMALL-CAP WINNERS & LOSERS: Go-Ahead suitor pulls out; Costain rises

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
1 Jul 2022 10:41

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
1 Jul 2022 08:56

LONDON MARKET OPEN: Recession fear hits stocks; Oxford Biomedica rises

(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates.

Read more
1 Jul 2022 08:31

Oxford BioMedica signs new Covid-19 vaccine deal with AstraZeneca

(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 08:07

LONDON BRIEFING: Oxford Biomedica signs new Covid jab deal with Astra

(Alliance News) - Oxford Biomedica on Friday said that it has signed a new three-year agreement with AstraZeneca, which would facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 07:48

LONDON MARKET PRE-OPEN: Oxford Biomedica inks new AstraZeneca jab deal

(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day.

Read more
1 Jul 2022 07:03

Oxford Biomedica signs new Covid vaccine deal with AstraZeneca

(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.

Read more
14 Jun 2022 11:16

US FDA lifts clinical hold on Oxford BioMedica partner's trial

(Alliance News) - Oxford BioMedica PLC on Tuesday noted that the US Food & Drug Administration lifted the clinical hold on Homology Medicines Inc's pheNIX gene therapy trial.

Read more
14 Jun 2022 09:35

Oxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria had been lifted.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.